Volume 24, Number 6—June 2018
CME ACTIVITY - Research
Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission
Maxime Hentzien
, Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, Moustapha Dramé, Firouzé Bani-Sadr, Jean-Marc Galempoix, Christophe Strady, Jean-Marc Reynes, Christian Penalba, and Amélie Servettaz
, Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, Moustapha Dramé, Firouzé Bani-Sadr, Jean-Marc Galempoix, Christophe Strady, Jean-Marc Reynes, Christian Penalba, and Amélie Servettaz
Table 3
Point value assigned for each predictive factor of severe nephropathia epidemica to be used for bioclinical assay to access risk for nephropathia epidemica severity*
| Predictive factor | Point value |
|---|---|
| Hematuria | 7 |
| Visual disorders | 8 |
| Leukocyte count >10 × 109 cells/L | 9 |
| Nephrotoxic drug exposure† | 10 |
| Thrombocytopenia <90 × 109/L | 11 |
*Predictive factors were assessed at admission.
†Nephrotoxic drugs included nonsteroidal antiinflammatory drugs, iodinated contrast media, diuretics, renin angiotensin aldosterone system inhibitors, and nephrotoxic antimicrobial drugs (aminoglycosides, glycopeptides).
Page created: May 15, 2018
Page updated: May 15, 2018
Page reviewed: May 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.